Bloodstream Infections in a COVID-19 Non-ICU Department: Microbial Epidemiology, Resistance Profiles and Comparative Analysis of Risk Factors and Patients' Outcome
- PMID: 35889033
- PMCID: PMC9318208
- DOI: 10.3390/microorganisms10071314
Bloodstream Infections in a COVID-19 Non-ICU Department: Microbial Epidemiology, Resistance Profiles and Comparative Analysis of Risk Factors and Patients' Outcome
Abstract
Background: Bloodstream infections (BSI) caused by highly resistant pathogens in non-ICU COVID-19 departments pose important challenges. Methods: We performed a comparative analysis of incidence and microbial epidemiology of BSI in COVID-19 vs. non-COVID-19, non-ICU departments between 1 September 2020-31 October 2021. Risk factors for BSI and its impact on outcome were evaluated by a case-control study which included COVID-19 patients with/without BSI. Results: Forty out of 1985 COVID-19 patients developed BSI. The mean monthly incidence/100 admissions was 2.015 in COVID-19 and 1.742 in non-COVID-19 departments. Enterococcus and Candida isolates predominated in the COVID-19 group (p < 0.001 and p = 0.018, respectively). All Acinetobacter baumannii isolates were carbapenem-resistant (CR). In the COVID-19 group, 33.3% of Klebsiella pneumoniae was CR, 50% of Escherichia coli produced ESBL and 19% of Enterococcus spp. were VRE vs. 74.5%, 26.1% and 8.8% in the non-COVID-19 group, respectively. BSI was associated with prior hospitalization (p = 0.003), >2 comorbidities (p < 0.001), central venous catheter (p = 0.015), severe SARS-CoV-2 pneumonia and lack of COVID-19 vaccination (p < 0.001). In the multivariate regression model also including age and multiple comorbidities, only BSI was significantly associated with adverse in-hospital outcome [OR (CI95%): 21.47 (3.86−119.21), p < 0.001]. Conclusions: BSI complicates unvaccinated patients with severe SARS-CoV-2 pneumonia and increases mortality. BSI pathogens and resistance profiles differ among COVID-19/non-COVID-19 departments, suggesting various routes of pathogen acquisition.
Keywords: COVID-19; SARS-CoV-2 pneumonia; antimicrobial resistance; bacteremia; bloodstream infections; catheter-related bloodstream infection; fungemia; multidrug resistant organisms.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


References
-
- Carbonell R., Urgelés S., Rodríguez A., Bodí M., Martín-Loeches I., Sole-Violan J., Díaz E., Gómez J., Trefler S., Vallverdú M., et al. Mortality comparison between the first and second/third waves among 3795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study. Lancet Reg. Health-Europe. 2021;11:100243. doi: 10.1016/j.lanepe.2021.100243. - DOI - PMC - PubMed
-
- Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFadden D.R., Soucy J.-P.R., Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin. Microbiol. Infect. 2020;26:1622–1629. doi: 10.1016/j.cmi.2020.07.016. - DOI - PMC - PubMed
-
- Musuuza J.S., Watson L., Parmasad V., Putman-Buehler N., Christensen L., Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS ONE. 2021;16:e0251170. doi: 10.1371/journal.pone.0251170. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous